google-site-verification=8uoYEkHPBfwioBbYA4utAsd7-39C4VHNUKlfRmSQA1E

SCOT-MED WILL DO ALL OF THE RESEARCH!

We're Small Enough To Be Agile But Large Enough To Deliver. A credit card is NOT required to register.

In order to protect confidential pricing, we require a registration from your Goverment/First Responders address.

 

Respiratory Test Kit Flowflex Plus COVID-19 and Flu A / B Home Test 1 Test per Kit 288/CS.

Log in for pricing

SKU:
SCM114564
Weight:
20.00 LBS
Shipping:
Calculated at Checkout

Product Description

Respiratory Test Kit Flowflex Plus COVID-19 and Flu A / B Home Test 1 Test per Kit 288S

ALSO SOLD: PER EACH OR 2 EACH PER PACK OR 12 EACH PER PACK 

Features
  • The Flowflex Plus COVID-19 and Flu A/B Home Test is for use under Emergency Use Authorization (EUA) only
  • The Flowflex Plus COVID-19 and Flu A/B Home Test is a lateral flow immunoassay intended for the qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B protein antigens
  • This test is authorized for non-prescription home use with self-collected anterior nares nasal swab specimens from individuals aged 14 years or older, or with adult-collected anterior nasal swab specimens from individuals two (2) years or older
  • This test is only authorized for individuals with sign and symptoms of respiratory infection consistent with COVID-19 within the first six (6) days of symptom onset when tested at least twice over three days with at least 48 hours between tests
  • Positive results indicate the presence of viral antigens, but the clinical correlation with patient history and other diagnostic information is necessary to determine infection status
  • Positive results do not rule out bacterial infection or co-infection with other viruses
  • Individuals who test positive with the Flowflex Plus COVID-19 and Flu A/B Home Test should self-isolate and seek follow up care with their physician or healthcare provider as additional testing may be necessary
  • All negative results are presumptive and confirmation with a molecular assay, if necessary for patient management, may be performed
  • Negative results do not rule out SARS-CoV-2, influenza A, and influenza B infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions such as isolating from others and wearing masks
  • Negative results should be considered in the context of an individual’s recent exposures, history, and the presence of clinical signs and symptoms consistent with SARS-CoV-2, influenza A, and influenza B infection
  • Easy to use
  • Quick results